← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,549	+15	+0.6%	$188B
2	2 Danaher DHR $158B	2,181	-22	-1%	$145B
3	3 Regeneron Pharmaceuticals REGN $80.1B	1,335	+23	+2%	$98.9B
4	4 Novartis NVS $279B	1,308	+53	+4%	$14.7B
5	5 Agilent Technologies A $49.1B	1,013	-2	-0.2%	$33B
6	6 Illumina ILMN $41B	775	-21	-3%	$14.7B
7	7 Charles River Laboratories CRL $14.4B	666	-10	-1%	$10.8B
8	8 Alnylam Pharmaceuticals ALNY $30B	523	+24	+5%	$29.1B
9	9 Revvity RVTY $17B	486	-40	-8%	$11.5B
10	10 Sarepta Therapeutics SRPT $1.78B	485	+70	+17%	$14B
11	11 CRISPR Therapeutics CRSP $4.86B	449	-34	-7%	$3.22B
12	12 DELISTED CATALENT, INC. CTLT	448	+6	+1%	$10.3B
13	13 GRAIL Inc GRAL $6.24B	372	+372	–	$333M
14	14 Bruker BRKR $8.47B	365	-23	-6%	$7.38B
15	15 Ionis Pharmaceuticals IONS $7.1B	357	-5	-1%	$6.83B
16	16 Azenta AZTA $1.63B	322	-7	-2%	$2.85B
17	17 Ginkgo Bioworks DNA $776M	313	-29	-8%	$312M
18	18 Qiagen QGEN $9.41B	306	+23	+8%	$6.22B
19	19 Intellia Therapeutics NTLA $1.6B	291	+6	+2%	$2.02B
20	20 Guardant Health GH $21.9B	282	+24	+9%	$3.32B
21	21 Ultragenyx Pharmaceutical RARE $1.47B	275	+5	+2%	$3.63B
22	22 Arrowhead Research ARWR $8.25B	272	-2	-0.7%	$2.54B
23	23 ARK Genomic Revolution ETF ARKG $2.05B	263	-23	-8%	$535M
24	24 Twist Bioscience TWST $9.82B	263	+25	+11%	$3.25B
25	25 10x Genomics TXG $9.52B	261	-29	-10%	$2.05B